Implantation of esterified hyaluronic acid in microdissected Reinke's space after vocal fold microsurgery: short- and long-term results.
In this study are reported the laryngeal and vocal results obtained after a microflap excision of benign vocal fold (VF) lesions and immediate implantation of esterified hyaluronic acid (EHA) in the surgical wound. In a previous pilot study on 11 cases, we have shown an excellent tolerance of this bioimplant. The objectives are to confirm the innocuity of the technique, to demonstrate the laryngeal and vocal evolution at short and long term, and to evaluate the eventual positive impact of EHA implantation on the pliability of the superficial layer of the lamina propria (SLLP) and on voice. This is a prospective and comparative study on 83 patients suffering from various benign VF lesions. Thirty-three patients were implanted with EHA, whereas 50 patients did not undergo implantation at the end of the microsurgical procedure. All patients undergo rigid laryngoscopy and microflap excision procedure under general anesthesia. After freeing up of the Reinke's space and creation of a mucosal microflap, a few fibers of EHA are inserted in the surgical wound, before closure of the incision with fibrin glue. Serial laryngeal and vocal assessments are performed in all patients using videostroboscopy (Wolff and Xion), perceptual and objective voice evaluation (MDVP software, Kay Elemetrics), and phonatory function measurements (Aerophone II). Pre- and early postoperative means are compared by analysis of variance. Delayed and long-term evolution of laryngeal and vocal data are compared by means of nonparametric statistical methods. The longest follow-up in the implanted group is 4 years. Early postoperative results are similar in both groups: a significant improvement of a majority of laryngeal and vocal data is observed after microsurgery. In the long term, the two groups exhibit a different behavior: further improvement of voice, as an ongoing process, is only observed in the EHA implanted group, together with improvement of some videostroboscopic characteristics. The nonimplanted group remains stable, with no further improvement of the voice quality obtained after microsurgery. Excellent short- and long-term tolerance of EHA implantation is confirmed by this larger series. The use of EHA implant in microdissected SLLP is safe and leads to good laryngeal and vocal outcomes in the treated patients. More interestingly, treated cases exhibit a continuous improvement over a long period of time.
Finck
Camille L
CL
Department of Otorhinolaryngology, University of Liège, Liège, Belgium. Camille.finck@chu.ulg.ac.be
Harmegnies
Bernard
B
Remacle
Angélique
A
Lefebvre
Philippe
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001530:Belgium; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D004343:Drug Implants; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D007818:Laryngeal Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D007828:Laryngoscopy; D008297:Male; D042282:Microdissection / Q000009:adverse effects; D008866:Microsurgery / Q000009:adverse effects; D011446:Prospective Studies; D020127:Recovery of Function; D049489:Stroboscopy; D013524:Surgical Flaps; D013997:Time Factors; D016896:Treatment Outcome; D014741:Video Recording; D014827:Vocal Cords / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery*; D014833:Voice Quality / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D004343:Drug Implants; D006820:Hyaluronic Acid